flupenthixol-decanoate and Parkinson-Disease--Secondary

Topics: Adult; Antipsychotic Agents; Contraindications; Delayed-Action Preparations; Flupenthixol; Humans; Male; Mental Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary

There are no data available on the risk of extrapyramidal symptoms when using long-term flupenthixol in low dosage in patients suffering from anxiety and depressive disorders. In a case control study 106 patients essentially treated with the neuroleptic flupenthixol in a so-called low, non-antipsychotic dosage were compared to n=37 otherwise comparable patients who never had been treated with neuroleptics. The investigator was blind to the previous treatment conditions. Extrapyramidal symptoms were found although with a low prevalence and mild degree: 6.7% tardive dyskinesia, none in controls; pseudoparkinsonism 26%, 16% in controls. Extrapyramidal side-effects, especially tardive dyskinesia, have to be considered in the individual weighing of therapeutic benefits and risks even when prescribing flupenthixol in low dosages.

Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Case-Control Studies; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Flupenthixol; Germany; Humans; Male; Middle Aged; Parkinson Disease, Secondary